TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
TherapeuticsMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.86−0.04 (-2.11%)
Close on Oct 19, 2026
- Market cap
- $21.66M
- P/E (TTM)
- –
- Dividend yield
- –
TherapeuticsMD, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and service revenue | – | – | – | – | – | – | – | – | – | $2.57M | $1.17M | $2.23M | – | – |
| BIJUVA [Member] | – | – | – | – | – | – | $10.56M | $11.19M | $10.69M | $10.58M | $10.14M | $8.49M | – | – |
| ANNOVERA [Member] | – | – | – | – | – | – | $45.03M | $46.42M | $37.70M | $37.94M | $39.20M | $33.81M | – | – |
| IMVEXXY [Member] | – | – | – | – | – | – | $27.25M | $28.32M | $31.49M | $31.53M | $33.69M | $32.51M | – | – |
| Prescription Vitamins [Member] | – | – | – | – | – | – | $4.23M | $4.68M | $5.18M | $5.73M | $6.59M | $7.69M | – | – |
| Product [Member] | – | – | – | – | – | – | $87.07M | $90.61M | $85.06M | $85.78M | $89.62M | $82.50M | – | – |
By region
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.86M | $1.79M | $1.70M | $1.63M | $1.09M | $1.12M | – | – | – | – | – | – | 55.5% | +70.3% |
| Non-U.S. [Member] | $1.49M | $1.23M | $1.10M | $928.00K | $748.00K | $638.00K | – | – | – | – | – | – | 44.5% | +99.5% |
From the segment and revenue-disaggregation notes of TherapeuticsMD's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.